New first-in-human study initiations feature yet more in vivo Car assets.
ApexOnco Front Page
Recent articles
Intismeran autogene’s Interpath-001 trial reads out this year.
Armed with $75m the company takes a risky asset into the clinic.
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
The biotech licenses a China-developed anti-B7-H3 ADC.
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
GEN1286 looks dead, though MCLA-129 continues for now.
And the company says it won’t need to carry out another trial.
